Unknown

Dataset Information

0

Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in mauritian cynomolgus monkeys vaccinated with Tat upon challenge with simian/human immunodeficiency virus SHIV89.6P.


ABSTRACT: The effects of the challenge dose and major histocompatibility complex (MHC) class IB alleles were analyzed in 112 Mauritian cynomolgus monkeys vaccinated (n = 67) or not vaccinated (n = 45) with Tat and challenged with simian/human immunodeficiency virus (SHIV) 89.6P(cy243.) In the controls, the challenge dose (10 to 20 50% monkey infectious doses [MID(50)]) or MHC did not affect susceptibility to infection, peak viral load, or acute CD4 T-cell loss, whereas in the chronic phase of infection, the H1 haplotype correlated with a high viral load (P = 0.0280) and CD4 loss (P = 0.0343). Vaccination reduced the rate of infection acquisition at 10 MID(50) (P < 0.0001), and contained acute CD4 loss at 15 MID(50) (P = 0.0099). Haplotypes H2 and H6 were correlated with increased susceptibility (P = 0.0199) and resistance (P = 0.0087) to infection, respectively. Vaccination also contained CD4 depletion (P = 0.0391) during chronic infection, independently of the challenge dose or haplotype.

SUBMITTER: Cafaro A 

PROVIDER: S-EPMC2919029 | biostudies-literature | 2010 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in mauritian cynomolgus monkeys vaccinated with Tat upon challenge with simian/human immunodeficiency virus SHIV89.6P.

Cafaro Aurelio A   Bellino Stefania S   Titti Fausto F   Maggiorella Maria Teresa MT   Sernicola Leonardo L   Wiseman Roger W RW   Venzon David D   Karl Julie A JA   O'Connor David D   Monini Paolo P   Robert-Guroff Marjorie M   Ensoli Barbara B  

Journal of virology 20100616 17


The effects of the challenge dose and major histocompatibility complex (MHC) class IB alleles were analyzed in 112 Mauritian cynomolgus monkeys vaccinated (n = 67) or not vaccinated (n = 45) with Tat and challenged with simian/human immunodeficiency virus (SHIV) 89.6P(cy243.) In the controls, the challenge dose (10 to 20 50% monkey infectious doses [MID(50)]) or MHC did not affect susceptibility to infection, peak viral load, or acute CD4 T-cell loss, whereas in the chronic phase of infection, t  ...[more]

Similar Datasets

| S-EPMC2865159 | biostudies-literature
| S-EPMC2687399 | biostudies-literature
| S-EPMC7649366 | biostudies-literature
| S-EPMC3077881 | biostudies-literature
| S-EPMC3416303 | biostudies-literature
| S-EPMC6761673 | biostudies-other
| S-EPMC1797269 | biostudies-literature
| S-EPMC7354885 | biostudies-literature
| S-EPMC5560087 | biostudies-literature
| S-EPMC10384433 | biostudies-literature